PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26076682-0	2015	First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	80-88	histone deacetylase 9	Homo sapiens	96-100
34397279-10	2021	CG200745 increased acetylation of histone H3 and MsrA levels in the mesenteric arteries while downregulating oxidative stress, inflammation, and vasocontractile proteins.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-8	H3 clustered histone 7	Mus musculus	34-44
21773733-0	2012	A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	39-47	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	126-131
21773733-0	2012	A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	39-47	BCL2 like 1	Homo sapiens	136-142
25781604-0	2015	Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	42-50	histone deacetylase 9	Homo sapiens	27-31
20978925-0	2012	Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	36-44	tumor protein p53	Homo sapiens	104-107
20978925-8	2012	CG200745 increased acetylation of p53 lysine residues K320, K373, and K382.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-8	tumor protein p53	Homo sapiens	34-37
34397279-10	2021	CG200745 increased acetylation of histone H3 and MsrA levels in the mesenteric arteries while downregulating oxidative stress, inflammation, and vasocontractile proteins.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-8	methionine sulfoxide reductase A	Mus musculus	49-53
28134290-0	2017	A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	24-32	histone deacetylase 9	Homo sapiens	8-12
31655853-0	2020	Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	30-38	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	104-118
31655853-10	2020	In conclusion, CG200745 ameliorated HFD-induced hypertension through inhibition of HDAC/Ang II/vascular contraction axis.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	15-23	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	88-94
32098220-2	2020	Here, we report the protective effect of CG200745 (CG), a novel histone deacetylase inhibitor, on tubulointerstitial fibrosis in Col4a3-/- mice, a murine model of Alport syndrome.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	41-49	collagen, type IV, alpha 3	Mus musculus	129-135
32098220-2	2020	Here, we report the protective effect of CG200745 (CG), a novel histone deacetylase inhibitor, on tubulointerstitial fibrosis in Col4a3-/- mice, a murine model of Alport syndrome.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	41-43	collagen, type IV, alpha 3	Mus musculus	129-135
32098220-3	2020	Morphological analyses revealed CG treatment markedly alleviated kidney fibrosis in Col4a3-/- mice at the age of 7 weeks.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	32-34	collagen, type IV, alpha 3	Mus musculus	84-90
32098220-4	2020	CG prevented the activation of transforming growth factor beta (TGFbeta) and its downstream SMAD signaling in the kidney of Col4a3-/- mice.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	transforming growth factor alpha	Mus musculus	64-71
32098220-4	2020	CG prevented the activation of transforming growth factor beta (TGFbeta) and its downstream SMAD signaling in the kidney of Col4a3-/- mice.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	collagen, type IV, alpha 3	Mus musculus	124-130
32098220-5	2020	As critical upstream regulators of TGFbeta signaling, immunoblotting of whole kidney lysate of Col4a3-/- mice reveled that intra-renal renin-angiotensin system (RAS) was activated with concurrent upregulation of inflammation and apoptosis, which were effectively suppressed by CG treatment.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	277-279	transforming growth factor alpha	Mus musculus	35-42
32098220-6	2020	CG suppressed both activation of RAS and up-regulation of TGFbeta signals in angiotensin II-stimulated HK-2 cells, a human kidney proximal tubular epithelial cell line.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	transforming growth factor alpha	Homo sapiens	58-65
32098220-6	2020	CG suppressed both activation of RAS and up-regulation of TGFbeta signals in angiotensin II-stimulated HK-2 cells, a human kidney proximal tubular epithelial cell line.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	angiotensinogen	Rattus norvegicus	77-91
32098220-7	2020	CG inhibited activation of TGFbeta-driven signals and fibrosis in NRK-49F cells, a rat kidney fibroblast cell line, under angiotensin II-rich conditions.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	transforming growth factor alpha	Rattus norvegicus	27-34
32098220-7	2020	CG inhibited activation of TGFbeta-driven signals and fibrosis in NRK-49F cells, a rat kidney fibroblast cell line, under angiotensin II-rich conditions.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	angiotensinogen	Rattus norvegicus	122-136
32098220-8	2020	Collectively, CG was found to be effective both in proximal tubular epithelial cells by inhibiting local RAS and TGFbeta signaling activation, as well as in fibroblasts by blocking their transition to myofibroblasts, attenuating renal fibrosis in a murine model of Alport syndrome.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	14-16	transforming growth factor alpha	Mus musculus	113-120
30099761-0	2019	Upregulation of C/EBPbeta and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	56-64	CCAAT/enhancer binding protein beta	Rattus norvegicus	16-25
30099761-0	2019	Upregulation of C/EBPbeta and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	56-64	TSC complex subunit 2	Rattus norvegicus	30-34
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-48	CREB regulated transcription coactivator 1	Mus musculus	113-119
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-48	CCAAT/enhancer binding protein beta	Rattus norvegicus	153-188
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-48	CCAAT/enhancer binding protein beta	Rattus norvegicus	190-200
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-48	TSC complex subunit 2	Rattus norvegicus	202-206
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-42	CREB regulated transcription coactivator 1	Mus musculus	113-119
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-42	CCAAT/enhancer binding protein beta	Rattus norvegicus	153-188
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-42	CCAAT/enhancer binding protein beta	Rattus norvegicus	190-200
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-42	TSC complex subunit 2	Rattus norvegicus	202-206
30099761-11	2019	CG treatment increased the expression of TSC2.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	TSC complex subunit 2	Rattus norvegicus	41-45
30099761-12	2019	In addition, CG treated rats showed an increased in the expression and acetylation of C/EBP-beta, owing to the increase in the recruitment of C/EBP-beta and Pol II at Tsc2 gene promoter.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	13-15	CCAAT/enhancer binding protein beta	Rattus norvegicus	86-96
30099761-12	2019	In addition, CG treated rats showed an increased in the expression and acetylation of C/EBP-beta, owing to the increase in the recruitment of C/EBP-beta and Pol II at Tsc2 gene promoter.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	13-15	CCAAT/enhancer binding protein beta	Rattus norvegicus	142-152
30099761-12	2019	In addition, CG treated rats showed an increased in the expression and acetylation of C/EBP-beta, owing to the increase in the recruitment of C/EBP-beta and Pol II at Tsc2 gene promoter.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	13-15	RNA polymerase II, I and III subunit F	Rattus norvegicus	157-163
30099761-12	2019	In addition, CG treated rats showed an increased in the expression and acetylation of C/EBP-beta, owing to the increase in the recruitment of C/EBP-beta and Pol II at Tsc2 gene promoter.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	13-15	TSC complex subunit 2	Rattus norvegicus	167-171
30099761-13	2019	Thus, CG ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling via upregulation of the C/EBP-beta/TSC2 pathway in DOCA-induced hypertensive rats.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	6-8	CREB regulated transcription coactivator 1	Mus musculus	67-73
30099761-13	2019	Thus, CG ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling via upregulation of the C/EBP-beta/TSC2 pathway in DOCA-induced hypertensive rats.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	6-8	CCAAT/enhancer binding protein beta	Rattus norvegicus	108-118
30099761-13	2019	Thus, CG ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling via upregulation of the C/EBP-beta/TSC2 pathway in DOCA-induced hypertensive rats.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	6-8	TSC complex subunit 2	Rattus norvegicus	119-123
30937691-0	2019	Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	54-62	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	141-146
30937691-0	2019	Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	54-62	BCL2 like 1	Homo sapiens	151-157
28134290-6	2017	CG200745 induced the expression of apoptotic proteins (PARP and caspase-3) and increased the levels of acetylated histone H3.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-8	poly(ADP-ribose) polymerase 1	Homo sapiens	55-59
28134290-6	2017	CG200745 induced the expression of apoptotic proteins (PARP and caspase-3) and increased the levels of acetylated histone H3.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-8	caspase 3	Homo sapiens	64-73
28134290-10	2017	The novel HDAC inhibitor, CG200745, with gemcitabine/erlotinib had a synergistic anti-tumor effect on pancreatic cancer cells.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	26-34	histone deacetylase 9	Homo sapiens	10-14